Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6116.0000 8.00 (0.13%)
NSE Apr 30, 2025 09:53 AM
Volume: 59,361
 

6116.00
0.13%
Motilal Oswal
Revenues grew 13% YoY to INR19.6b (our est: INR19.9b) for the quarter. The gross margin expanded 420bp YoY to 67.2%. This was largely owing to a superior product mix and lower raw material costs. The EBITDA margin expanded at a lower rate of 300bp YoY to 43.5% (our est: 40.9%) due to higher employee costs (+60bps as a percentage of sales) and other expenses (+60bps as a percentage of sales) EBITDA was up 22% to INR8.5b (our est: INR8.1b) for the quarter YoY. Adjusted for INR196m in forex gains, PAT grew at a lower rate of 13% YoY to...
Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.
More from Divi's Laboratories Ltd.
Recommended